Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
ConclusionsBased on the present analysis, apixaban represents a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with AF from a Greek healthcare payer perspective over a lifetime horizon.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Aspirin | Atrial Fibrillation | Cardiology | Cardiovascular | Clinical Trials | Coumadin | Diabetes | Disability | Endocrinology | Heart | Heart Attack | Hemorrhagic Stroke | Hospital Management | Hypertension | Ischemic Stroke | Stroke | Vitamins | Warfarin